The use of febuxostat in comorbid patients with gout in real clinical practice: own data
Objective: to evaluate the efficacy and safety of febuxostat (Azuriks®) in the treatment of patients with gout and concomitant diseases.Patients and methods. An observational, open-label, single-centre study of the results of febuxostat use in 85 gout patients with insufficient prior allopurinol eff...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2022-06-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1301 |
| _version_ | 1797876698810679296 |
|---|---|
| author | E. V. Zonova D. N. Orlov A. S. Kabargina |
| author_facet | E. V. Zonova D. N. Orlov A. S. Kabargina |
| author_sort | E. V. Zonova |
| collection | DOAJ |
| description | Objective: to evaluate the efficacy and safety of febuxostat (Azuriks®) in the treatment of patients with gout and concomitant diseases.Patients and methods. An observational, open-label, single-centre study of the results of febuxostat use in 85 gout patients with insufficient prior allopurinol efficacy or its intolerance. The median age of patients was 56.2 [49; 59] years, among them 83.5% were men. All patients had comorbid diseases, mainly cardiovascular pathology (76.5%) and chronic kidney disease (60%). The achievement of target values of uric acid (UA) during 4 months of urate-lowering therapy and its safety were assessed.Results and discussion. After 4 months of therapy with febuxostat, 25% of patients reached the target values of UA. Exacerbations at an early stage of the use of urate-lowering therapy were rare and were characterized by a lesser severity of the articular syndrome. Normalization of purine metabolism was accompanied by a decrease in the laboratory activity index (CRP level) to values corresponding to the interictal period of gout. Febuxostat was well tolerated.Conclusion. According to the data obtained, in patients with gout and concomitant diseases, febuxostat allows reaching target UA values in a short time without dose titration, while a high safety profile is noted. |
| first_indexed | 2024-04-10T02:05:42Z |
| format | Article |
| id | doaj.art-c581cb3754534bfa97910db980288a92 |
| institution | Directory Open Access Journal |
| issn | 1996-7012 2310-158X |
| language | Russian |
| last_indexed | 2024-04-10T02:05:42Z |
| publishDate | 2022-06-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj.art-c581cb3754534bfa97910db980288a922023-03-13T08:39:29ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2022-06-01163758010.14412/1996-7012-2022-3-75-802484The use of febuxostat in comorbid patients with gout in real clinical practice: own dataE. V. Zonova0D. N. Orlov1A. S. Kabargina2ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России; ГАУЗ НСО «Городская клиническая поликлиника №1», Городской центр клинической иммунологииГАУЗ НСО «Городская клиническая поликлиника №1», Городской центр клинической иммунологии; ООО «Медицинский центр «Здоровая семья»ООО «Медицинский центр «Здоровая семья»Objective: to evaluate the efficacy and safety of febuxostat (Azuriks®) in the treatment of patients with gout and concomitant diseases.Patients and methods. An observational, open-label, single-centre study of the results of febuxostat use in 85 gout patients with insufficient prior allopurinol efficacy or its intolerance. The median age of patients was 56.2 [49; 59] years, among them 83.5% were men. All patients had comorbid diseases, mainly cardiovascular pathology (76.5%) and chronic kidney disease (60%). The achievement of target values of uric acid (UA) during 4 months of urate-lowering therapy and its safety were assessed.Results and discussion. After 4 months of therapy with febuxostat, 25% of patients reached the target values of UA. Exacerbations at an early stage of the use of urate-lowering therapy were rare and were characterized by a lesser severity of the articular syndrome. Normalization of purine metabolism was accompanied by a decrease in the laboratory activity index (CRP level) to values corresponding to the interictal period of gout. Febuxostat was well tolerated.Conclusion. According to the data obtained, in patients with gout and concomitant diseases, febuxostat allows reaching target UA values in a short time without dose titration, while a high safety profile is noted.https://mrj.ima-press.net/mrj/article/view/1301подагракоморбидностьфебуксостатгиперурикемияэффективностьбезопасность |
| spellingShingle | E. V. Zonova D. N. Orlov A. S. Kabargina The use of febuxostat in comorbid patients with gout in real clinical practice: own data Современная ревматология подагра коморбидность фебуксостат гиперурикемия эффективность безопасность |
| title | The use of febuxostat in comorbid patients with gout in real clinical practice: own data |
| title_full | The use of febuxostat in comorbid patients with gout in real clinical practice: own data |
| title_fullStr | The use of febuxostat in comorbid patients with gout in real clinical practice: own data |
| title_full_unstemmed | The use of febuxostat in comorbid patients with gout in real clinical practice: own data |
| title_short | The use of febuxostat in comorbid patients with gout in real clinical practice: own data |
| title_sort | use of febuxostat in comorbid patients with gout in real clinical practice own data |
| topic | подагра коморбидность фебуксостат гиперурикемия эффективность безопасность |
| url | https://mrj.ima-press.net/mrj/article/view/1301 |
| work_keys_str_mv | AT evzonova theuseoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata AT dnorlov theuseoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata AT askabargina theuseoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata AT evzonova useoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata AT dnorlov useoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata AT askabargina useoffebuxostatincomorbidpatientswithgoutinrealclinicalpracticeowndata |